AzTrials
AzTrials

Atrial Fibrillation (AF)NCT07483008

3D Printing Technology For Planning Left Atrial Appendage Occlusion

A study testing 3D-printed models of the left atrial appendage and Standard preoperative planning in people with Atrial Fibrillation (AF) and 3D Printing, run by Chinese University of Hong Kong at 1 site in Hong Kong.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Atrial fibrillation is the most common cardiac arrhythmia, affecting 8.5% of the general population in Hong Kong. Systemic embolization, and particularly stroke, is the most frequent major complication of atrial fibrillation. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
3D-printed models of the left atrial appendage and Standard preoperative planning
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
184 participants
Where
1 siteHong Kong
Study dates
1 Oct 2017to 31 Jan 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years
  • Non-valvular atrial fibrillation
  • CHA2DS2-VASc ≥2
  • Absolute or relative contraindications to long-term oral anticoagulation (e.g. history of intracranial or life-threatening bleeding, HAS-BLED ≥3, triple anticoagulant therapy)
  • Planned for LAAO procedure

Who cannot join

  • Intracardiac thrombus is visualized by echocardiographic imaging
  • An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present
  • The LAA anatomy will not accommodate a device
  • Any of the customary contraindications for other percutaneous catheterization procedures (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present.
  • Known hypersensitivity to any portion of the device material or the individual components
  • Comorbidities other than atrial fibrillation that required oral anticoagulation
  • Suboptimal LAA image on TEE or CT that is inadequate for 3D modelling and printing
  • Refusal to participate the study

Trial locations and contacts

1 site in 1 country.

Hong Kong1 site
  • Division of Cardiology, Department of Medicine and Therapeutics Faculty of Medicine, The Chinese University of Hong Kong

    Hong Kong, New Territories, Sha Tin

Other trials in Hong Kong

About this study

Official title: 3D Printing Technology For Planning Left Atrial Appendage Occlusion: A Randomised Trial

Atrial fibrillation is the most common cardiac arrhythmia, affecting 8.5% of the general population in Hong Kong. Systemic embolization, and particularly stroke, is the most frequent major complication of atrial fibrillation. Long-term oral anticoagulation is recommended for most atrial fibrillation patients for prevention of embolism. However, such therapy is associated with an increased risk of bleeding and not all individuals are candidates for this therapy.

The left atrial appendage (LAA) is the usual source for clot that embolizes. Occlusion of the LAA ostium (LAAO) with percutaneous device in patients with nonvalvular atrial fibrillation has emerged as an alternative to anticoagulation for prevention of embolism.

Read more

Procedural success requires careful planning and understanding of the anatomy of LAA, as well as the interaction between the appendage and the occlusion device. However, complexity and variability of LAA anatomy exists and these anatomical variations among individuals poses challenges to accurately sizing and positioning the device. Certain anatomic variations of the appendage, for instance the presence of a sharp bend in the proximal or middle portion of the dominant lobe, or prominent pectinate muscles, pose particular challenge to device implantation and demands pre-specified implantation technique. Assessment of LAA anatomy relies on imaging, usually combining peri-interventional 2D transesophageal echocardiography (TEE) with fluoroscopy guidance and, less frequently, with pre-interventional computed tomography (CT). Because lobes of the LAA exist in different planes, imaging must be done in multiple planes to visualize the entire LAA. Even with advanced imaging, complete understanding the 3D geometry of the appendage is challenging, and the mechanical interaction between the device and the anatomy is difficult to predict or quantify.

The limitation of imaging in the assessment of LAA anatomy may lead to inaccurate device sizing. Over- or under-sizing increase the chance of pericardial effusion, incomplete occlusion, and device embolization. Incomplete occlusion of the LAA ostium is common and may jeopardise the procedural efficacy in embolism prevention. Device re-sizing during procedure prolongs procedural time as well as radiation exposure; moreover, device re-positioning within the appendage may cause inadvertent tissue injury and increase the risk of cardiac perforation. Indeed, procedural complication rate of LAAO remains fairly high in real-world practice.

3D printing (3DP) is a novel technology able to create a patient-specific model of any given anatomical portion of the heart for preoperative device testing and procedural simulation. The simulation "rehearsal" experience can enhance the operator's confidence, allowing the operator to anticipate difficulties before the actual intervention; this potentially reduces the procedural time (hence cost and radiation hazard), device re-sizing, the number of deployment attempts, and promotes procedural success.

The aim of this project is to evaluate the effect of 3D-printed patient-specific LAA model compared with standard imaging planning on procedural efficacy and safety of LAAO.

The project will be divided into two parts:

Part I Technical validation of 3D-printed LAA models Validation of anatomical accuracy and material properties of the 3D-printed LAA model will be conducted in 30 patients referred for clinically indicated surgical excision of the LAA.

Part II Randomised clinical trial on additive benefit of 3D printing for LAAO. The investigators will conduct a randomized, controlled, open-label, trial in 200 patients undergoing LAAO for stroke prevention in our hospital.

Eligible subjects will be randomly assigned by a computer program in a 1:1 ratio to either preoperative planning using 3D-printed LAA model (3D printing arm) or standard imaging planning alone (no-3D printing arm).

The investigators hypothesize that preoperative 3DP planning could help in finding the correct position within LAA, sizing the device and guiding the choice of the closure device despite the measurements provided by imaging alone.

Being tested
3D-printed models of the left atrial appendage, Standard preoperative planning
Keywords
3D printing, Left Atrial Appendage Occlusion, Atrial Fibrillation
Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 3D-printed models of the left atrial appendageDevice

    Participants receive preoperative planning using patient-specific 3D-printed models of the left atrial appendage. This arm includes procedural simulation with different occlusion devices and sizes to optimize the intervention.

  • Standard preoperative planningOther

    Participants undergo standard preoperative planning based solely on traditional imaging techniques, such as 2D/3D transesophageal echocardiography (TEE) and optionally computed tomography (CT).

Study groups in NCT07483008
Study groupRoleWhat they receive
3D printing armActive comparatorIn the 3D printing arm, pliable 3D-printed LAA models will be created 1 week before the planned LAAO procedure using methodology described above. Preoperative procedural simulation will be conducted by testing different types (Watchman [Boston Scientific Inc.] and Amplatzer Amulet [St Jude Inc.]) and sizes (21-33mm for Watchman, 16-34mm for Amulet) of locally available LAAO devices on the 3D-printed pliable appendage model to determine the optimal device type and size that achieve proper positioning, stability, and complete occlusion of the ostium.
Receives: Device: 3D-printed models of the left atrial appendage
Non 3D printing armOtherIn the no-3D printing arm, standard preoperative planning based on preoperative imaging, namely, multi-planar 2D/3D TEE and, in selected cases at the physician's discretion, pre-interventional CT.
Receives: Other: Standard preoperative planning

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To assess the rate of complete occlusion of the ostium

    This will be determined by the absence of peri-device flow on color Doppler imaging or if the jet width is less than 1 mm.

    Measured: The occlusion rate will be assessed during the procedure and at the 45-day TEE follow-up

Secondary outcomes (1)
  1. Procedural complications

    Pericardial effusion, cardiac perforation, device embolization, procedure-related stroke, bleeding.

    Measured: During the procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Mar 2026
  2. Study start1 Oct 2017
  3. Primary completion31 Jan 2022
  4. Study completion31 Jan 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
184 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07483008
Sponsor's protocol ID
2017.397-T
Status last verified
Mar 2026
First submitted
6 Mar 2026
Last updated
19 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing 3D-printed models of the left atrial appendage and Standard preoperative planning in people with Atrial Fibrillation (AF) and 3D Printing, run by Chinese University of Hong Kong at 1 site in Hong Kong.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To assess the rate of complete occlusion of the ostium (time frame: The occlusion rate will be assessed during the procedure and at the 45-day TEE follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in